Related references
Note: Only part of the references are listed.Mutations in K-ras and Epidermal Growth Factor Receptor Expression in Korean Patients With Stages III and IV Colorectal Cancer
Won-Suk Lee et al.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2011)
Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients
Hong Shen et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study
Adam Naguib et al.
BMC CANCER (2010)
Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer
Zuo Yunxia et al.
BMC MEDICAL GENETICS (2010)
Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer
Inti Zlobec et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
KRAS Mutation Comparison of Testing Methods and Tissue Sampling Techniques in Colon Cancer
Wilbur A. Franklin et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2010)
Assessment of K-ras Mutation A Step Toward Personalized Medicine for Patients With Colorectal Cancer
Yixing Jiang et al.
CANCER (2009)
KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis
Paloma Cejas et al.
PLOS ONE (2009)
K-Ras mutation status as a predictive biomarker in metastatic colorectal cancer
Francisco Javier Ramos et al.
BIOMARKERS IN MEDICINE (2008)
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab
Minaxi Jhawer et al.
CANCER RESEARCH (2008)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma
A Conlin et al.
GUT (2005)
BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors
N Lubomierski et al.
CANCER (2005)
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
A Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study
M Brink et al.
CARCINOGENESIS (2003)
Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype
V Bazan et al.
ANNALS OF ONCOLOGY (2002)
Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study
HJN Andreyev et al.
BRITISH JOURNAL OF CANCER (2001)
Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma
B Baisse et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Blocking oncogenic Ras signaling for cancer therapy
AA Adjei
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Dose-dependent effect of dietary meat on endogenous colonic N-nitrosation
R Hughes et al.
CARCINOGENESIS (2001)
Share Paper
